Associations between sympathetic activity, plasma concentrations of renin, aldosterone, and parathyroid hormone, and the degree of intractability of blood pressure control in hemodialysis patients

Journal of Korean Medical Science

Volumn 22, Issue 4, 2007, Pages 604-610

  Hong, Zoong Rock ^a   Gil, Hyo Wook ^a   Yang, Jong Oh ^a   Lee, Eun Young ^a   Ahn, Jae Ouk ^a   Hong, Sae Yong ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Hemodialysis; Hyperparathyroidism; Hypertension

Indexed keywords

EID: 34548555623     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2007.22.4.604     Document Type: Article

References (30)

1. Acosta JH. Hypertension in chronic renal disease. Kidney Int 1982; 22: 702-12.
2. Agarwal R, Nissenson AR, Battle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291-7.
3. Horl MP, Horl WH. Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 2002; 39: 227-44.
4. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
5. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK; HEMO Study Group. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280-8.
6. Esler M, Julius S, Zewifler A, Randall O, Harburg E, Gardiner H, DeQuattro V. Mild high-renin essential hypertension: Neurogenic human hypertension? N Engl J Med 1977; 296: 405-11.
7. Fink GD, Bruner CA, Mangiapane ML. Area postrema is critical for angiotensin-induced hypertension in rats. Hypertension 1987; 9: 355-61.
8. Mangiapane ML, Brody MJ. Vasoconstrictor and vasodilator sites within anteroventral third ventricle region. Am J Physiol 1987; 253: 827-31.
9. Bruner CA, Mangiapane ML, Fink GD, Webb RC. Area postrema ablation and vascular reactivity in deoxycorticosterone-salt-treated rats. Hypertension 1988; 11: 668-73.
10. Zimmerman BG. Adrenergic facilitation by angiotensin: does it serve a physiological function? Clin Sci 1981; 60: 343-8.
11. Zimlichman R, Goldstein DS, Zimlichman S, Stull R, Keiser HR. Angiotensin II increases cytosolic calcium and stimulates catecholamine release in cultured bovine adrenomedullary cells. Cell Calcium 1987; 8: 315-25.
12. Textor SC, Gavras H, Tifft CP, Bernard DB, Idelson B, Brunner HR. Norepinephrine and rennin activity in chronic renal failure. Evidence for interacting roles in hemodialysis hypertension. Hypertension 1981; 3: 294-9.
13. Baldamus CA, Ernst W, Frei U, Koch KM. Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy. Nephron 1982; 31: 324-32.
14. Zucchelli P, Catizone L, Esposti ED, Fusaroli M, Ligabue A, Zuccala A. Influence of ultrafiltration on plasma renin activity and adrenergic system. Nephron 1978; 21: 317-24.
15. Cuche JL, Prinseau J, Selz F, Ruget G, Baglin A. Plasma free, sulfoand glucuro-conjugated catecholamines in uremic patients. Kidney Int 1986; 30: 566-72.
16. Resnick LM. Calcium metabolism in hypertension and allied metabolic disorders. Diabetes Care 1991; 14: 505-20.
17. Raine AE, Bedford L, Simpson AW, Ashley CC, Brown R, Woodhead JS, Ledingham JG. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43: 700-5.
18. Iseki K, Massry SG, Campese VM. Effects of hypercalcemia and PTH on blood pressure in normal and renal-failure rats. Am J Physiol 1986; 250: 924-9.
19. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12: 2427-33.
20. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-8.
21. Zoccali C, Ciccarelli M, Mallamaci F, Maggiore Q, Stornello M, Valvo E, Scapellato L. The role of endogenous opioids in the baroreflex dysfunction of dialysis patients. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 190-4.
22. Guo GB, Abboud FM. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol 1984; 246: 80-9.
23. Pickering TG, Gribbin B, Oliver DO. Baroreflex sensitivity in patients on long-term hemodialysis. Clin Sci 1972; 43: 645-7.
24. Waston AJ, Di Pette D. Baroreflex sensitivity and pressor response in a rat model of uremia. Clin Sci 1985; 69: 637-40.
25. Teranishi Y, Sugino H, Ozono R, Ishioka N, Kumazaki T, Tsuru H. Contribution of endogenous vasopressin to regional hemodynamics in borderline-hypertensive Hiroshima rats. Hypertens Res 2002; 25: 241-8.
26. Kario K, Mitsuhashi T, Shimada K. Neurohumoral characteristics of older hypertensive patients with abnormal nocturnal blood pressure dipping. Am J Hyperten 2002; 15: 531-7.
27. Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J Hypertens 2005; 23: 1831-7.
28. Steiner S, Schaller G, Puttinger H, Fodinger M, Kopp CW, Seidinger D, Grisar J, Horl WH, Minar E, Vychytil A, Wolzt M, Sunder-Plassmann G. History of cardiovascular disease is associated with endothelial progenitor cells in peritoneal dialysis patients. Am J Kidney Dis 2005; 46: 520-8.
29. Silva JA, Chan AW, White CJ, Collins TJ, Jenkins JS, Reilly JP, Ramee SR. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation 2005; 111: 328-33.
30. Chan JC, Knudson O, Wu F, Morser J, Dole WP, Wu Q. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci USA 2005; 102: 785-90.